Description

Cimacef (cefuroxime) 1.5 g. vial intravenous №1

Ingredients

Active ingredient: Cefuroxime. Other ingredients may include sodium carbonate, sodium citrate, and water for injection.

Dosage

Dosage: The usual adult dosage is 750 mg to 1.5 grams every 8 hours, depending on the severity of the infection.

Indications

Indicated for: Treatment of infections caused by susceptible bacteria, including lower respiratory tract, skin and skin structure, urinary tract, bone and joint, and septicemia.

Contraindications

Contraindications: Do not use in patients with known hypersensitivity to cefuroxime or other cephalosporins.

Directions

Administration: Administer by intravenous infusion over 30 minutes. Dosage and duration of therapy should be determined by the severity of the infection.

Scientific Evidence

Cefuroxime, the active ingredient in Cimacef, has been extensively studied for its efficacy in treating various bacterial infections. Research published in the Journal of Antimicrobial Chemotherapy has shown cefuroxime to be effective against a wide range of pathogens, making it a valuable option in the treatment of serious infections.

Additional Information

It is important to complete the full course of treatment with Cimacef as prescribed by a healthcare provider to ensure the infection is fully eradicated and to prevent the development of antibiotic resistance. Consult a healthcare professional if any adverse reactions occur during treatment.

Pharmacological Effects: Cefuroxime works by interfering with the synthesis of the bacterial cell wall, leading to the death of the bacteria. It exhibits bactericidal activity against a wide range of gram-positive and gram-negative bacteria.

Clinical Trials: Clinical trials have demonstrated the efficacy of cefuroxime in treating various infections, with a favorable safety profile. A study published in the International Journal of Infectious Diseases showed that cefuroxime was well-tolerated and effective in the treatment of community-acquired pneumonia.